Product Detail
®Product Resources
Related Products & Services
DMX has value for...
Benefits of DMX®
The benefits of deploying DMX within a drug development enterprise are:
Address “What-If” Questions on Product Attributes for More Confident Decision-Making
DMX offers a flexible browser-based software application to help project teams build consensus on likely product profiles and understand key tradeoffs versus competing therapies. DMX provides ready access to a database of simulated drug-model responses, facilitating quantitative answers to key development questions. The ability to answer “what if” questions in a team meeting, for example, is often difficult to achieve with a standard slide presentation.
Lower Technical Barriers to Understanding and Using Model-Based Results
DMX makes the information contained in drug models substantially more accessible to project teams and decision-makers. Project team members, not expert modelers, make queries and select DMX views. Experience with DMX views creates confidence that a given drug model accurately represents important drug characteristics, and increases trust in quantitative models to provide an integrated assessment of a compound’s likely performance.
Knowledge Management Within and Across Development Programs
DMX provides centralized management of model-based results, serving as a project-based database that can be easily updated when new information becomes available. The DMX visual presentation structure is applicable across drug programs, allowing teams to share information rapidly and clearly and to make consistent comparisons of development program alternatives.
Advanced Technology, Scalability and Ease of Deployment
DMX is designed with components that are compatible with pharmaceutical industry standards and existing technology infrastructure. The DMX web client requires no installation on individual user machines. DMX-ready data are centrally stored and securely managed, and easy-to-use publishing tools are designed to support rapid update cycles to incorporate new model-based information at any stage of compound development.